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Introduction
Mycobacterium tuberculosis and other members of the
M tuberculosis complex use several strategies to resist the
action of antimicrobial agents. First, the mycobacterial cell
is surrounded by a specialized, highly hydrophobic cell wall
that results in decreased permeability to many compounds
(Fig. 1) [1,2]. Active drug efflux systems and degrading or
inactivating enzymes, and the genes that are associated
with these functions, have been found in M tuberculosis
[3,4]. However, genetic studies have shown that resistance
of M tuberculosis to antimycobacterial drugs is the conse-
quence of spontaneous mutations in genes that encode
either the target of the drug, or enzymes that are involved in
drug activation. Resistance-associated point mutations,
deletions, or insertions have been described for all first-line
drugs (isoniazid, rifampin, pyrazinamide, ethambutol, and
streptomycin), and for several second-line and newer drugs
(ethionamide, fluoroquinolones, macrolides, nitroimidazopy-
rans) [5–8]. However, no single genetic alteration has yet
been found that results in the MDR phenotype (defined as
resistance at least to isoniazid and rifampin). Rather, MDR
develops by sequential acquisition of mutations at different
loci, usually because of inappropriate patient treatment.
Because MDR strains are the result of cumulative mutations,
growth of M tuberculosis can successfully be controlled in
the host by concomitant treatment with more than one drug.
Thus, treatment regimens that consist of three to four drugs
are used routinely to treat patients with tuberculosis.
The World Health Organization [9] has recently recom-
mended the following terminology changes for the differ-
ent types of resistance to antituberculosis drugs. Isolation
of drug-resistant M tuberculosis from patients without a
history of previous treatment should be referred to as ‘drug
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resistance among new cases’ (instead of ‘primary resis-
tance’). Isolation of a drug-resistant strain from patients
who have been treated for tuberculosis for at least 1 month
should be referred to as ‘drug resistance among previously
treated patients’ (instead of ‘acquired resistance’). The
more common of these occurrences is ‘drug resistance
among previously treated patients’, in which inadequate
treatment or lack of adherence by the patient results in the
selection of naturally occurring resistant mutants [10]. Less
common is cross-resistance, in which resistance occurs
between drugs that are chemically related and/or have a
similar target within the mycobacterial cell (ie rifampin and
other rifamycin derivatives, or isoniazid and ethionamide)
[11,12]. However, the in vivo relevance of the cross-resis-
tance seen in vitro is not always clear.
The present review gives a concise summary of the mech-
anism of action and the molecular basis of resistance to
isoniazid, rifampin, and pyrazinamide, the three most
important antituberculosis drugs. In addition, the impor-
tance of using molecular assays for the rapid detection of
drug-resistant strains of M tuberculosis is emphasized.
Isoniazid
Isoniazid is a pro-drug that requires activation in isoniazid-
susceptible mycobacterial species. Based on in vitro
experiments, it has been proposed [13] that the activation
of isoniazid results in a number of highly reactive species
that are capable of either oxidizing or acylating groups in
proteins. However, the actual form of isoniazid that is
active in vivo is still unknown. It was observed soon after
Figure 1
Previously demonstrated and proposed sites of action of isoniazid (INH), pyrazinamide (PZA), and rifampin (RMP) on the M tuberculosis cell. INH
inhibits the synthesis of mycolic acids [19,20], PZA inhibits the synthesis of short-chain, fatty-acid precursors [32], and RMP inhibits transcription
by binding to the b-subunit of RNA polymerase [28]. This figure is adapted in part from Parsons et al [40].Respiratory Research    Vol 2 No 3 Somoskovi et al
isoniazid was introduced in the 1950s that isoniazid-resis-
tant clinical isolates frequently lost catalase and peroxi-
dase activity [14]. However, the association of this enzyme
with isoniazid activation was not proven until the early
1990s, when the primary mycobacterial catalase-peroxi-
dase gene (katG) was cloned and sequenced [15]. That
study and others [8,16] revealed that mutations in this
gene are found in 42–58% of isoniazid-resistant clinical
isolates. A large number of different mutations have been
described thus far; however, the Ser315Thr mutation is
found most often, occurring in approximately 40% of all
isoniazid-resistant strains [8,16,17]. The Ser315Thr
mutation results in an enzyme without the ability to activate
isoniazid, but retains approximately 50% of its catalase-
peroxidase activity [18]. Thus, the altered catalase-peroxi-
dase provides high-level resistance to isoniazid, while
retaining a level of oxidative protection that is sufficient to
enable the organism to maintain detoxifying activity against
host antibacterial radicals. Isolates that carry other, less
frequently occurring mutations in katG have been
described as exhibiting varying levels of isoniazid resis-
tance and catalase-peroxidase activity [8,16–18].
Significant evidence supports the concept that isoniazid
blocks the synthesis of cell-wall mycolic acids, the major
components of the envelope of M tuberculosis (Fig. 1).
Two intracellular targets for the drug are currently being
actively investigated [19,20]: the fatty-acid enoyl-acyl
carrier protein reductase (InhA), and a complex of an acyl
carrier protein (AcpM) and a b-ketoacyl-ACP synthase
(KasA). These enzymes are involved in synthesis of
mycolic acids, and mutations have been found in the pro-
moter regions, or less commonly in the genes that encode
these proteins (inhA, acpM, and kasA), in clinical isolates
that exhibit low-level resistance to isoniazid (for review
[8]). It is proposed that over-expression of one or more of
these target proteins may be the reason for isoniazid resis-
tance in these strains. However, the role of kasA muta-
tions in isoniazid resistance is presently unclear, because
similar mutations were also found in isoniazid-susceptible
isolates, and, in cases of isoniazid resistance, mutations
were also found in katG or inhA [21,22].
Mutations in the promoter region of a gene that encodes
an alkyl hydroperoxidase reductase (ahpC) have been
found in approximately 10% of isoniazid-resistant isolates,
but mutations in katG were also found in these isolates
[8,16,23]. The resulting over-expression of alkyl hydroper-
oxidase reductase may compensate for the loss of cata-
lase-peroxidase activity in these mycobacteria [24].
Rifampin
One of the main reasons for treatment failure and fatal
clinical outcome in tuberculosis patients is resistance to
rifampin [25]. In addition to a significant early bactericidal
effect on metabolically active M tuberculosis, rifampin also
exhibits excellent late sterilizing action on semidormant
organisms undergoing short bursts of metabolic activity.
The recognition of this late effect of rifampin, and the addi-
tional effectiveness of pyrazinamide, has allowed for the
reduction of routine tuberculosis treatment from 1 year to
6 months [26,27]. Whereas monoresistance to isoniazid is
quite common, monoresistance to rifampin is rare. Instead,
rifampin resistance occurs most often in strains that are
also resistant to isoniazid; thus, rifampin resistance can be
used as a surrogate marker for MDR.
The mechanism of action of rifampin is to inhibit mycobacter-
ial transcription by targeting DNA-dependent RNA poly-
merase (Fig. 1). The development of resistance to rifampin is
due to mutations in a well-defined, 81 base pair (bp)
(27 codons) central region of the gene that encodes the
b-subunit of RNA polymerase (rpoB) [28]. More than 96% of
the rifampin-resistant strains contain a mutation in this 81 bp
region of rpoB, thus facilitating a straightforward approach to
detecting rifampin resistance and/or MDR rapidly [8,16].
The most common mutations (65–86%) alter either codon
526 or codon 531, and result in high-level resistance to
rifampin (minimal inhibitory concentration [MIC]
>32mg/ml). However, not all mutations within the 81 bp
region exhibit the same level of resistance. For example,
alterations in codons 511, 516, 518, and 522 result in
organisms that have low-level resistance to rifampin and
another rifamycin derivative (rifapentin), but remain suscep-
tible to two other rifamycins (rifabutin and rifalazyn) [29,30]
(Parsons LM, unpublished data). Rare mutations associ-
ated with rifampin resistance have also been found in the
amino-terminal region of rpoB [8,31]. Most reference labo-
ratories that use molecular methods examine only the
81 bp region. However, it is advisable to screen for amino-
terminal mutations in cases in which rifampin resistance is
suspected, but no mutation is found in the 81 bp region.
Pyrazinamide
Pyrazinamide has an excellent sterilizing effect on semidor-
mant tubercle bacilli and, when used in combination with
rifampin, shortens the duration of treatment of tuberculosis
patients from 1 year to 6 months [26]. Pyrazinamide, a
nicotinamide analog that is believed to target an enzyme
involved in fatty-acid synthesis [32], is a pro-drug that is
converted to its active form (pyrazinoic acid [POA]) by the
mycobacterial enzyme pyrazinamidase. In M tuberculosis,
an accumulation of intracellular POA occurs when the
extracellular pH is acidic. Experimental evidence suggests
that pyrazinamide diffuses into M tuberculosis in a passive
manner, is converted into POA by pyrazinamidase, and,
because of an inefficient efflux system, accumulates in
huge amounts in the bacterial cytoplasm [33,34]. The
accumulation of POA lowers the intracellular pH to a sub-
optimal level that is likely to inactivate a vital target enzyme
such as fatty acid synthase I [32].Available online http://respiratory-research.com/content/2/3/164
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It has been observed that the pyrazinamide-resistant
M tuberculosis  isolates usually lose their pyrazinamidase
activity [35]. After cloning and sequencing the gene that
encodes pyrazinamidase (pncA), it was found that
72–97% of all pyrazinamide-resistant clinical isolates
tested carry a mutation in the structural gene or in the
putative promoter region of the gene [8,36]. However, the
involvement of other mechanisms (ie those that involve
pyrazinamide uptake, pncA regulation, or POA efflux) is
indicated by the existence of isolates that exhibit a high
level of pyrazinamide resistance without mutations in the
pncA gene [37]. Two other members of the M tuberculo-
sis  complex,  M bovis and  M bovis BCG, are naturally
resistant to pyrazinamide. In these organisms, pyrazi-
namide resistance is due to a unique C to G point muta-
tion in codon 169 of pncA. In contrast, mutations in
pyrazinamide-resistant M tuberculosis have been found
scattered throughout pncA [36].
Conclusion
The action and mechanism of resistance to the three
most important antituberculosis drugs are still not fully
understood. However, current molecular evidence indi-
cates that routine application of rapid molecular tests in
the clinical management of drug-resistant tuberculosis is
essential. Many approaches have been used success-
fully to detect and identify the most common mutations
associated with drug resistance [8,16,38]. In many
instances, the knowledge gained from determining the
particular mutation can provide significant information on
the following: drug resistance, the level of resistance,
cross-resistance to similar drugs, relatedness of strains,
and virulence.
Total dependence on results that are provided 2–4
weeks (or even months) later by the conventional ‘gold
standard’ susceptibility methods might not be sufficient
for optimal patient outcome. The tuberculosis laboratory
should no longer allow its pace to be dictated by the slow
growth of the pathogenic mycobacteria. Rather, the labo-
ratory is a vital part of a renewed global commitment that
is aimed at the elimination of tuberculosis [39]. The ulti-
mate goals are provision of timely, appropriate, and ade-
quate services. These must be provided, and continually
evaluated and updated. A highly infectious tuberculosis
patient must have access to state-of-the-art laboratory
services, even if the patient resides in an area where a
local laboratory is not capable of providing those ser-
vices. Innovative ideas, such as centralized testing by a
large public health laboratory, may be required to achieve
this goal. District, state, or national boundaries should not
limit access to these laboratory services. The benefits of
providing new and more clinically relevant assays to a
larger population, especially in high-incidence regions of
the world, would be of great public health significance to
all populations.
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